Re-Thinking Rare Disease

13 Sep 2022

• By Melanie Senior

Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.

Swan — Orphan drugs are classified as those destined for fewer than five in 10,000 people in Europe • Source: Shutterstock

Re-Thinking Rare Disease

More from Market Access

More from In Vivo